ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Cbrain A/s

Cbrain A/s (0DWV)

40.00
0.00
(0.00%)
Cerrado 05 Enero 10:30AM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
40.00
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
213
0.00 Rango del Día 0.00
40.00 Rango de 52 semanas 40.00
Capitalización de Mercado [m]
Precio Anterior
40.00
Precio de Apertura
-
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
926
Acciones en circulación
19,563,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
12.39
Beneficio por acción (BPA)
3.23
turnover
239.18M
Beneficio neto
63.18M

Acerca de Cbrain A/s

Sector
Prepackaged Software
Industria
Computer Software/svcs Diverse
Sitio web
Sede
Copenhagen, Dnk
Fundado
2005
Cbrain A/s is listed in the Prepackaged Software sector of the London Stock Exchange with ticker 0DWV. The last closing price for Cbrain A/s was kr40. Over the last year, Cbrain A/s shares have traded in a share price range of kr 40.00 to kr 40.00.

Cbrain A/s currently has 19,563,000 shares in issue. The market capitalisation of Cbrain A/s is kr782.52 million. Cbrain A/s has a price to earnings ratio (PE ratio) of 12.39.

0DWV Últimas noticias

cBrain executes growth plan, remaining on target

cBrain executes growth plan, remaining on target Company Announcement no. 11/2024 cBrain executes growth plan, remaining on target Copenhagen, November 7, 2024 Driven by expanding partnerships...

cBrain lowers expected yearly revenue growth to 10-15%, but maintains EBT margin of 24-28%

cBrain lowers expected yearly revenue growth to 10-15%, but maintains EBT margin of 24-28% Company Announcement no. 10/2024 cBrain lowers expected yearly revenue growth to 10-15%, but maintains...

On track with Growth Plan

On track with Growth Plan Company Announcement no. 09/2024 On track with Growth Plan Copenhagen, August 21, 2024 Revenue grew by +6% to DKK 139m in the first half of 2024, up from DKK 132m in the...

Minutes of meeting from AGM 2024

Minutes of meeting from AGM 2024 Company Announcement no. 08/2024 Minutes of meeting from AGM 2024 Copenhagen, April 24, 2024 At cBrain's (NASDAQ: CBRAIN) ordinary general meeting on April 24 The...

cBrain takes lead within AI for government

cBrain takes lead within AI for government Company Announcement no. 07/2024 cBrain takes lead within AI for government Copenhagen, April 24, 2024 cBrain (NASDAQ: CBRAIN) entered 2024 on the back...

Reporting of transactions made by persons discharging managerial responsibilities

Reporting of transactions made by persons discharging managerial responsibilities   Company Announcement no. 06/2024 Reporting of transactions made by persons discharging managerial...

cBrain releases first F2 standard module for government AI

cBrain releases first F2 standard module for government AI   Company Announcement no. 04/2024 cBrain releases first F2 standard module for government AI   Copenhagen, March 14, 2024   In close...

In 2023 cBrain grew revenue by 27% and delivered record high earnings before tax margin (EBT margin) of 34%

In 2023 cBrain grew revenue by 27% and delivered record high earnings before tax margin (EBT margin) of 34% Company Announcement no. 03/2024 In 2023 cBrain grew revenue by 27% and delivered...

cBrain guides continued growth and solid earnings in 2024 and suggests a dividend raise by 33%

cBrain guides continued growth and solid earnings in 2024 and suggests a dividend raise by 33%   Company Announcement no. 02/2024 cBrain guides continued growth and solid earnings in 2024 and...

cBrain beats expectations on top and bottom lines as subscription revenue jumps

cBrain beats expectations on top and bottom lines as subscription revenue jumps Company Announcement no. 01/2024 cBrain beats expectations on top and bottom lines as subscription revenue...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10040404029640DE
40040404025540DE
120040404092640DE
260040404060340DE
520040404063840DE
1560040404054040DE
2600040404038140DE

0DWV - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Cbrain A/s?
El precio actual de las acciones de Cbrain A/s es kr 40.00
¿Cuántas acciones de Cbrain A/s están en circulación?
Cbrain A/s tiene 19,563,000 acciones en circulación
¿Cuál es la capitalización de mercado de Cbrain A/s?
La capitalización de mercado de Cbrain A/s es DKK 782.52M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Cbrain A/s?
Cbrain A/s ha negociado en un rango de kr 40.00 a kr 40.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Cbrain A/s?
El ratio precio/beneficio de Cbrain A/s es 12.39
¿Cuál es el ratio de efectivo a ventas de Cbrain A/s?
El ratio de efectivo a ventas de Cbrain A/s es 3.27
¿Cuál es la moneda de reporte de Cbrain A/s?
Cbrain A/s presenta sus resultados financieros en DKK
¿Cuál es el último ingresos anual de Cbrain A/s?
El último ingresos anual de Cbrain A/s es DKK 239.18M
¿Cuál es el último beneficio anual de Cbrain A/s?
El último beneficio anual de Cbrain A/s es DKK 63.18M
¿Cuál es la dirección registrada de Cbrain A/s?
La dirección registrada de Cbrain A/s es DAMPFAERGEVEJ 30, COPENHAGEN, 2100
¿Cuál es la dirección del sitio web de Cbrain A/s?
La dirección del sitio web de Cbrain A/s es www.cbrain.dk
¿En qué sector industrial opera Cbrain A/s?
Cbrain A/s opera en el sector COMPUTER SOFTWARE/SVCS DIVERSE

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M
boi568 boi568 7 minutos hace
That spike to $31.50 was not organic and it was clearly generated by a big player. I have always thought it was an engineered mini-short squeeze.
AVXL
Mr. Bill Mr. Bill 19 minutos hace
https://www.goodrx.com/well-being/sleep/how-to-sleep-with-sciatica
nowwhat2 nowwhat2 21 minutos hace
Could still just be climbing in sympathy w overall crypto mkt

Scathingly poor outlooks

https://www.youtube.com/watch?v=EOsjnOUAw14



https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg

WONDF
DonVance DonVance 23 minutos hace
This will hit 1k this year I believe now.
MSTR
georgejjl georgejjl 24 minutos hace
How many of the 7 million Alzheimer’s patients in the USA are projected to be treated with the MAB infusions during 2025???

How many people with Alzheimer’s in the USA are projected to be treated with donepezil (Aricept) or memantine during 2025???

The treatment used t
AVXL
Mr. Bill Mr. Bill 24 minutos hace
Stretches https://www.healthline.com/health/back-pain/sciatic-stretches#sitting-spinal-stretch
Graniteguy Graniteguy 26 minutos hace
Doc and Investor posters here tend to be negatively biased which you whole heartedly champion, especially "Doc" who's medical opinion is at best questionable, and incredibly biased, to fit a narrative of constant failure for Anavex's Blarcamesine. The fact that you pile onto their "steaming pile of
AVXL
BDEZ BDEZ 28 minutos hace
The Russes hit the jackpot?
BDEZ BDEZ 29 minutos hace
40% of homicides in the US take place in districts with a Soros-funded prosecutor.

Biden gave him a Medal Of Freedom.

https://x.com/EndWokeness/status/1875725808071012529
BDEZ BDEZ 29 minutos hace
Not good, thanks for sharing.
sand sand 36 minutos hace
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 37 minutos hace
Moving hard soon 
EFSH
mining101 mining101 38 minutos hace
Superb
MEGL
benz280c benz280c 45 minutos hace
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 52 minutos hace
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 52 minutos hace
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 56 minutos hace
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 1 hora hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 1 hora hace
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 1 hora hace
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 1 hora hace
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 1 hora hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 1 hora hace
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT

Su Consulta Reciente

Delayed Upgrade Clock